Clinical Trials
35 trialsNCT06248411 2026-05-27
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT07205718 2026-05-22
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Takeda
Phase 1/2 Recruiting
NCT04843709 2026-05-15
A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2 Completed
NCT06074497 2026-04-29
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
Phase 1 Active not recruiting
NCT07260305 2026-04-24
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
NCT05848466 2026-03-30
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Completed
NCT06234397 2026-03-11
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT05957081 2025-12-30
MarkV-01
PharmAbcine
Phase 1 Recruiting
NCT06724016 2025-12-17
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT04381650 2025-12-10
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Completed
NCT06752681 2025-10-10
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Recruiting
NCT06548217 2025-07-03
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05785754 2025-06-26
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1 Recruiting
NCT03155061 2025-06-05
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05598151 2025-04-30
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT04572152 2025-02-28
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
Akeso
Phase 1 Completed
NCT01928394 2024-12-27
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03316638 2024-12-10
Ulysse
Pierre Fabre Medicament
Phase 1/2 Terminated
NCT02261532 2024-11-14
A Phase I Study of TAS-102 in Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT06196762 2024-10-10
Phase I of XKH002 Injection in Patients
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase 1 Unknown
NCT05399654 2024-08-16
INCLINE-101
Tallac Therapeutics
Phase 1/2 Active not recruiting
NCT05693844 2024-05-10
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05483530 2024-04-16
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT05496595 2024-03-06
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1 Terminated
NCT03730337 2023-10-04
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT05388279 2023-03-23
A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT05652855 2023-01-09
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
Minghui Pharmaceutical Pty Ltd
Phase 1/2 Not yet recruiting
NCT05407909 2022-08-09
To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Unknown
NCT03248843 2022-02-08
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed
NCT04427774 2021-07-20
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT02220049 2016-03-25
VELDAY
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT02004548 2015-12-29
Phase I Clinical Study of Metatinib Tromethamine Tablet
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT00276913 2014-02-03
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT01014429 2012-09-07
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences
Phase 1 Completed
NCT01506934 2012-08-28
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
Abbott
Phase 1 Terminated